I. Start the exam by click the “Start” button
Disorders of Platelets and Vessel Wall- Part 2
II. See all quizzes of the Disorders of Platelets and Vessel Wall at here:
Disorders of Platelets and Vessel Wall- Part 1 |Disorders of Platelets and Vessel Wall- Part 2 |Disorders of Platelets and Vessel Wall- Part 3 |Disorders of Platelets and Vessel Wall- Part 4
1. All IVIgG immunoglobulin preparations are derived from ?
A. Human plasma
B. Horse plasma
C. Bovine plasma
D. Pig plasma
2. In ITP, total dose of IVIgG is ?
A. 1 gram / kg
B. 2 gram / kg
C. 3 gram / kg
D. 4 gram / kg
3. Which of the following drugs is useful in refractory ITP ?
A. Rituximab
B. Romiplostim
C. Eltrombopag
D. All of the above
4. Large platelets is a feature of which of the following ?
A. May-Hegglin anomaly
B. Sebastian syndrome
C. Epstein’s syndrome
D. All of the above
5. Autosomal recessive inherited thrombocytopenic disorders include ?
A. Congenital amegakaryocytic thrombocytopenia
B. Thrombocytopenia with absent radii
C. Bernard Soulier syndrome
D. All of the above
6. Which of the following is inherited as X-linked pattern in inherited thrombocytopenia ?
A. May-Hegglin anomaly
B. Wiskott-Aldrich syndrome
C. Fechtner syndrome
D. Bernard Soulier syndrome
7. Which of the following is false regarding thrombotic thrombocytopenic microangiopathies ?
A. Thrombocytopenia
B. Laboratory evidence of hemolysis
C. Abnormal PT and aPTT
D. Microvascular thrombosis
8. Thrombotic thrombocytopenic purpura (TTP) was first described by ?
A. Balint
B. Eli Moschcowitz
C. Verner-Morrison
D. Wiskott-Aldrich
9. Which of the following is not a feature of TTP ?
A. Microangiopathic hemolytic anemia
B. Renal failure
C. Hepatic failure
D. Neurologic dysfunction
10. Upshaw-Schulman syndrome is related to ?
A. Multiple transfusions
B. Thrombotic thrombocytopenic purpura
C. Uremia
D. CHF
11. Upshaw-Schulman syndrome is best related to ?
A. Idiopathic TTP
B. Inherited TTP
C. Medication-related TTP
D. TTP in pregnant women
12. Idiopathic TTP is more common in ?
A. Women
B. HIV infection
C. Pregnant women
D. All of the above
13. Which of the following antiplatelet agent has been implicated in the causation of TTP ?
A. Aspirin
B. Ticlopidine
C. Carvadilol
D. All of the above
14. In TTP, hyaline thrombi without inflammatory changes in vessel wall may be found in ?
A. Arterioles
B. Capillaries
C. Venules
D. All of the above
15. Severity of TTP is estimated by the degree of ?
A. Anemia
B. Thrombocytopenia
C. Serum LDH level
D. All of the above
16. Which of the following is not a feature of TTP ?
A. Severe Coombs-positive hemolytic anemia
B. Near normal prothrombin time
C. Near normal fibrinogen level
D. Near normal FDP level
17. Which of the following supports the diagnosis of TTP ?
A. Increased lactate dehydrogenase
B. Increased indirect bilirubin
C. Decreased haptoglobin
D. All of the above
18. Mainstay of treatment of idiopathic TTP is ?
A. Rituximab
B. IV Ig
C. Plasma exchange
D. Splenectomy
19. Which of the following is false about TTP ?
A. TTP is more common in HIV patients and pregnant women
B. Coagulation studies are essentially normal in TTP
C. Severe bleeds are usually absent
D. None of the above
20. Which of the following is false about Weibel-Palade bodies ?
A. Are organelles in the vascular endothelium
B. Major constituents of Weibel-Palade bodies are von Willebrand factor (vWF) and P-selectin
C. George Emil Palade won the Nobel Prize in Physiology or Medicine in 1974
D. None of the above
21. Which of the following is false about Weibel-Palade bodies (WPBs) ?
A. Weibel-Palade bodies play a dual role in blood coagulation hemostasis and inflammation
B. Weibel-Palade bodies are the main source of vWF
C. Weibel-Palade bodies are secretory organelles used for post-synthesis storage in endothelial cells.
D. None of the above
22. TTP is due to deficiency in the activity of ?
A. ADAMTS 11
B. ADAMTS 12
C. ADAMTS 13
D. ADAMTS 14
23. Which of the following is related to TTP ?
A. ADAMTS-10
B. ADAMTS-11
C. ADAMTS-12
D. ADAMTS-13
24. Which of the following is false about ADAMTS-13 ?
A. ADAMTS-13 prevents inappropriate microvascular platelet aggregation
B. Deficiency of ADAMTS-13 is a finding for TTP
C. vWf multimers is the physiologic substrate for ADAMTS-13
D. None of the above